Australia's Saluda Medical climbs on strong revenue growth, forecast hike
** Saluda Medical SLD.AX rise as much as 17% to A$0.690, their biggest gain since February 26 ** Medtech firm Q3 global revenue surges 34% to $23.8 million from prior corresponding period ** Hikes FY26 revenue forecast to $87 million from $85.0 million ** Around 2.2 mln shares change hands, nearly 10.5x 30-day average ** SLD down 56.5% YTD (Reporting by Keshav Singh Chundawat in Bengaluru) ((Keshav.singhchundawat@thomsonreuters.com))
Recent news on Saluda Medical
See all newsBrief: Saluda Medical Initiates Voluntary Field Action For Certain Evoke® System Devices
Saluda Medical's shares hit record low on Evoke device recall
Australia's Saluda Medical hits record low on voluntary device field action
Brief: Saluda Medical Expands Access To FDA-Approved Closed-Loop Surgical Paddle Lead
Brief: Saluda Medical Appoints Mike Mathias As CEO Replacing Barry Regan